Advertisement

European Journal of Clinical Pharmacology

, Volume 37, Issue 1, pp 29–32 | Cite as

Plasma protein binding of alpidem in healthy volunteers, in neonates and in liver or renal insufficiency

  • G. M. Pacifici
  • G. Bianchetti
  • A. Viani
  • G. Rizzo
  • M. Carrai
  • J. Allen
  • P. L. Morselli
Originals
  • 24 Downloads

Summary

The binding of alpidem, a new anxiolytic drug, has been studied in plasma from 6 healthy subjects, 12 patients with renal failure, 12 patients with liver cirrhosis and 12 chronic uraemics maintained on haemodialysis, as well as in 12 serum samples from the placental cord, to represent the situation in the newborn.

The unbound fraction was 0.61% (healthy volunteers), 1.31% (newborns), 0.86% (cirrhotic patients), 0.72 (patients with renal failure), 0.70% (before haemodialysis) and 0.79% (after haemodialysis). Binding in the volunteers was significantly different from that in neonates and cirrhotics only.

Alpidem became bound to isolated albumin (45 g·l−1) and alpha1-acid glycoprotein (0.75 g·l−1) to 97.2% and 97.1%, respectively. The bound fraction of the drug in a mixture of two proteins was 99.1%.

For alpidem, it appears that alpha1-acid glycoprotein may balance the effect of any decrease in the albumin concentration.

Key words

alpidem cirrhotics anxiolytics placental serum renal failure plasma protein binding neonates 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dimsdale M, Friedmann JC, Morselli PL, Zivkovic B (1988) Alpidem. Drugs Future 13: 106–109Google Scholar
  2. 2.
    Langer SZ, Arbilla S (1988) Imidazopyridines as a tool for the characterization of benzodiazepine receptors: A proposal for a pharmacological classification as omega receptor subtypes. Pharmacol Biochem Behav 29: 763–766Google Scholar
  3. 3.
    Curran HV, Allen D, Lader M (1987) The effects of single doses of alpidem and corazepam on memory and psychomotor performance in normal humans. J Psychopharmacol 1: 65–73Google Scholar
  4. 4.
    Musch B, Morselli PL, Priore P (1988) Clinical studies with the new anxyolitic alpidem in anxious patients: An overview of the european experiences. Pharmacol Biochem Behav 29: 805–806Google Scholar
  5. 5.
    Hindmarch I, Shillingford C, Shillingford J, Baksi A, Graham D, Guillet Ph (1988) The pharmacodynamic effect of alpidem in elderly subjects. J Drug Dev 1: 77–85Google Scholar
  6. 6.
    Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951) Protein measurement with phenol Folin reagent. J Biol Chem 193: 265–275Google Scholar
  7. 7.
    Mancini G, Carbonara AO, Heremans JF (1965) Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2: 235–254Google Scholar
  8. 8.
    Blascke TF (1977) Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 2: 32–44Google Scholar
  9. 9.
    Piafsky KM (1980) Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 5: 246–262Google Scholar
  10. 10.
    Tillement JP, Lhoste F, Giudicelli JF (1978) Diseases and drug protein binding. Clin Pharmacokinet 3: 144–154Google Scholar
  11. 11.
    Morselli PL, Franco-Morselli R, Bossi L (1980) Clinical pharmacokinetics in newborns and infants. Age related differences and therapeutic implications. Clin Pharmacokinet 5: 485–527Google Scholar
  12. 12.
    Pacifici GM, Viani A, Rizzo G, Carrai M, Ganansia J, Bianchetti G, Morselli PL (1988) Plasma protein binding of zolpidem in liver and renal insufficiency. Clin Pharmacol Ther Toxicol 26: 439–443Google Scholar
  13. 13.
    Pacifici GM, Viani A, Taddeucci-Brunelli G, Rizzo G, Carrai M, Schulz HU (1986) Effects of development, aging, renal and hepatic insufficiency as well as haemodialysis on the plasma concentrations of albumin and alpha-1-acid glycoprotein: Implications for binding of drugs. Ther Drug Monit 8: 259–263Google Scholar
  14. 14.
    Baruzzi A, Contin M, Perucca E, Albani F, Riva R (1986) Altered serum protein binding of Carbamazepine in disease states associated with an increased alpha1-acid glycoprotein concentration. Eur J Clin Pharmacol 31: 85–89Google Scholar
  15. 15.
    Shand DG (1984) Alpha1-acid glycoprotein and plasma lidocaine binding. Clin Pharmacokinet 9 [Suppl 1]: 27–31Google Scholar
  16. 16.
    Siddoway LA, Woosley RL (1986) Clinical pharmacokinetics of disopyramide. Clin Pharmacokinet 11: 214–222Google Scholar
  17. 17.
    Fraeyman NF, Dello CD, Belpaire FM (1988) Alpha1-acid glycoprotein concentration and molecular heterogeneity: Relationship to oxprenolol binding in serum from healthy volunteers and patients with lung carcinoma or cirrhosis. Br J Clin Pharmacol 25: 733–740Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • G. M. Pacifici
    • 1
  • G. Bianchetti
    • 2
  • A. Viani
    • 2
  • G. Rizzo
    • 3
  • M. Carrai
    • 4
  • J. Allen
    • 2
  • P. L. Morselli
    • 2
  1. 1.Department of General Pathology, Medical SchoolUniversity of PisaItaly
  2. 2.Department of Clinical ResearchSYNTHELABO RECHERCHEParisFrance
  3. 3.Department of NephrologyHospital of PisaItaly
  4. 4.Department of GastroenterologyHospital of PisaItaly

Personalised recommendations